3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neoplasms
4
Breast Neoplasms
4
Neoplasm Metastasis
3
Lung Neoplasms
3
Triple Negative Breast Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Glioblastoma
2
Colorectal Neoplasms
2
Stroke
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neurologic Manifestations
1
Myelodysplastic Syndromes
1
Motor Activity
1
Melanoma
1
Margins of Excision
1
Malignant Solid Neoplasm
1
Malignant Female Reproductive System Neoplasm
1
Localized Head and Neck Carcinoma
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Inflammatory Breast Neoplasms
1
Hematologic Neoplasms
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Depression
1
Communication
1
Interventions
lutetium Lu 177 dotatate
12
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
cabozantinib
5
Everolimus
5
pembrolizumab
4
Nivolumab
4
olaparib
3
lenvatinib
3
Cyclophosphamide
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
lanreotide
2
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Phantoms, Imaging
2
Octreotide
2
Lutetium-177
2
Ipilimumab
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
tivozanib
1
surufatinib
1
repotrectinib
1
peposertib
1
pazopanib
1
entrectinib
1
belinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Palliative Care
×
90 days
×
Clear all
No trials found.